Abstract
Iodine kinetics were studied in patients with differentiated thyroid cancer while euthyroid under exogenous thyroid stimulating hormone (TSH) and while hypothyroid to detect differences in radioiodine uptake, distribution and elimination. Nine patients with total or near-total thyroidectomy on thyroid hormone suppressive therapy received two or three daily doses of 0.9 mg recombinant human TSH (rhTSH) followed by administration of a diagnostic activity of 2 mCi (74 MBq) iodine-131. After the biokinetics assessments had been performed, patients stopped taking thyroid hormones to become hypothyroid. A second 2 mCi (74 MBq) diagnostic activity of 131I was administered, followed by a second set of biokinetics assessments. One week later the patients underwent remnant ablation with a therapeutic activity of 131I. A comparison of the 131I kinetics in the patients while euthyroid and while hypothyroid showed major differences in the doses to the remnant as well as in residence times and radiation exposure to the blood. In the first diagnostic assessment the remnant dose was higher in eight of the nine patients and clearance of the activity from the blood was faster in all of them. The data from this study suggest that radioiodine administration is potent and safe when administered to euthyroid patients following rhTSH administration. Enhanced residence time in the remnant and decreased radiation exposure to the blood were noted when patients were euthyroid compared to when they were rendered hypothyroid. However, all patients received diagnostic activities in the same order: first while euthyroid, followed by hypothyroidism. It is quite possible that "stunning" from the radioiodine administered in the initial uptake study inhibited the subsequent uptake of radioiodine by the remnant lesions in the second uptake study.
Similar content being viewed by others
References
Hurley J, Becker D. Treatment of thyroid cancer with radioiodine (131I). In: Sandler M, Coleman R, Wackers F, Patton J, Gottschalk A, Hoffer P, eds. Diagnostic nuclear medicine. Philadelphia: Lippincott Williams and Wilkins; 1996:959–989.
Maxon HR, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990; 19:685–718.
Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418–428.
Wong J, Kaplan M, Meyer K, Pauker S. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma: a decision analytic perspective. Endocrinol Metab Clin North Am 1990; 19:741–760.
Bal C, Padhy A, Jana S, Pant G, Basu A. Prospective randomized clinical trial to evaluate the optimal dose of I131 for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996; 77:2574–2580.
Maxon H, Englaro E, Thomas S, Hertzberg V, Hinnefeld J, Chen L, Smith H, Cummings D, Aden M. Radioiodine-131 therapy for well-differnentiated thyroid cancer—a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992; 33:1132–1136.
Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002; 12:37–43.
Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337:888–896.
Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994; 78:188–196.
Park S, Reynolds J, Brucker-Davis F. Iodine kinetics during131I scanning in patients with thyroid cancer: comparison studies with recombinant human TSH (rhTSH) vs. hypothyroidism [abstract]. J Nucl Med 1996; 37 (Suppl):15P.
Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, Smith A, Drucker WD. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86:619–625.
Vitale G, Lupoli G, Ciccarellei A, Fonderico F, Klain M, Squame G, Salvatore M, Lupoli G. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol 2001; 56:247–252.
Snyder WS, Ford MR, Warner GG. S—absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet 11. New York: Society of Nuclear Medicine, 1975.
Thomas SR, Samaratunga RC, Sperling M, Maxon HR 3rd. Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer. Nucl Med Biol 1993; 20:157–162.
Akabani G, Poston JW Sr. Absorbed dose calculations to blood and blood vessels for internally deposited radionuclides. J Nucl Med 1991; 32:830–834.
Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84:3877–3885.
McDougall IR. 74 MBq radioiodine131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997; 18:505–512.
Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, Ghossein R, Tuttle RM. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 2002; 43:1482–1488.
Guiraud-Vitaux F, Feldmann G, Vadrot N, Charles-Gupta S, Durand-Schneider A, Colas-Linhart N, Petiet A. Early ultrastructural injuries in the thyroid of the normal rat radioinduced by diagnostic and/or therapeutic amounts of iodine-131. Cell Mol Biol 2001; 47:495–502.
Kogai T, Endo T, Saito T, Miyazaki A, Kawaguchi A, Onaya T. Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology 1997; 138:2227–2232.
Kao C and Yen T. Stunning effects after a diagnostic dose of iodine-131. Nuklearmedizin 1998; 37:30–32.
Morris LF, Waxman AD, Braunstein GD. The nonimpact of thyroid stunning: remnant ablation rates in131I-scanned and nonscanned individuals. J Clin Endocrinol Metab 2001; 86:3507–3511.
Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994; 4:49–54.
Park HM, Park YH, Zhou XH. Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid 1997; 7:277–280.
De Geus-Oei LF, Oei HY, Hennemann G, Krenning EP. Sensitivity of 123-I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2002; 29:768–774.
Gerard SK, Cavalieri RR. I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours. Clin Nucl Med 2002; 27:1–8.
Sarkar SD, Kalapparambath TP, Palestro CJ. Comparison of123I and 131I for whole-body imaging in thyroid cancer. J Nucl Med 2002; 43:632–634.
Mandel SJ, Shankar LK, Benard F, Yamamoto A, Alavi A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001; 26:6–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Luster, M., Sherman, S.I., Skarulis, M.C. et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 30, 1371–1377 (2003). https://doi.org/10.1007/s00259-003-1230-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-003-1230-1